Ongeveer 10 uur geleden - Universiteit van Amsterdam (UvA) - Amsterdam
De Afdeling Algemene Rechtsleer zoekt een Universitair Hoofddocent Rechtstheorie/ Inleiding tot het Recht. Als Universitair Hoofddocent zul je …
This post is available for a fixed term of two years to undertake research in relation to the complement system in age-related macular degeneration (AMD).
This post is available for a fixed term of two years to undertake research in relation to the complement system in age-related macular degeneration (AMD). AMD is the leading cause of vision loss among the elderly. There are important medical needs for new therapies, for instance drugs with improved efficacy in AMD patients who present a suboptimal response to anti-VEGF therapy, and in patients with geographic atrophy, a form of advanced AMD for which there is no approved therapy.
Genetic evidence for the role of the alternative complement pathway in AMD is overwhelming, with several common and rare variants in genes coding for complement proteins strongly associated with AMD risk. Nevertheless, several attempts of targeting the complement system with pharmacologic agents so far have failed in clinical trials. The goal of this project is to gain better understanding in the role of the complement system in AMD, in order to identify the most suitable targets in the complement system, identify the patients which could benefit from a treatment targeting the complement system, and identify biomarkers for proof-of-mechanism in clinical trials.
The postdoc will work in a multidisciplinary team at the Department of Ophthalmology at the Radboudumc in Nijmegen, the Netherlands. The project is funded by a Roche postdoctoral fellowship, and will be performed in close collaboration with researchers at Roche Pharma Research in Basel, Switserland. The postdoc will be based in Nijmegen, the Netherlands and will spend up to 6 months in Basel, Switserland.
Tasks and responsibilities
Read more about the Radboudumc employment conditions.
Additional information about the vacancy can be obtained from Prof. Anneke den Hollander, Professor of Molecular Ophthalmology or from Dr.Eiko de Jong.
Applicants should send a letter of intent outlining special interest in the position, overall related qualifications, experience and career goals, a curriculum vitae and names and addresses of professional references.
This vacancy is open until filled.
Use the Apply button to submit your application.
Radboudumc strives to be a leading developer of sustainable, innovative and affordable healthcare to improve the health and wellbeing of people and society in the Netherlands and beyond. This is the core of our mission: To have a significant impact on healthcare. To get a better picture of what this entails, check out our strategy film.
Our key strength is medical life-sciences and clinical practice, with an impressive infrastructure comprising state-of-the-art technology platforms and (translational) research facilities. The Radboudumc is therefore uniquely positioned in the emerging Euregio and Dutch healthcare infrastructure to play a leading role in the new healthcare paradigm of prediction, prevention and personalised medicine.
The Radboudumc focuses on scientific health challenges of today, with an eye on emerging diseases of the future.
Read more about what it means to work at Radboudumc and how you can do your part.
The research project will be based at the Departments of Ophthalmology and Human Genetics, and will be performed in close collaboration with Roche Pharma Research in Basel, Switserland. The Department of Ophthalmology is embedded in the Donders Institute for Brain, Cognition and Behaviour of the Radboud University Medical Center. We provide a stimulating work environment within a group of enthusiastic clinical and non-clinical researchers with a strong national and international research network.
The Departments of Ophthalmology and Human Genetics house a range of top researchers in the areas of ophthalmology, genetics, molecular biology and bioinformatics. Both departments have a strong track record, with recent publications in high-impact journals (Nature, Nature Genetics, Ophthalmology, JAMA Ophthalmology). The combined infrastructure is state-of-the-art including innovative genetic technologies (Next-Generation Sequencing, bioinformatics core), -omics technologies for biomarker discovery (Radboudumc Technology Center for mass spectrometry), and a wide range of functional assays and model systems.